Glaukos Profit Margin 2014-2022 | GKOS

Current and historical gross margin, operating margin and net profit margin for Glaukos (GKOS) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Glaukos net profit margin as of September 30, 2022 is -31.45%.
Glaukos Annual Profit Margins
Glaukos Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $2.263B $0.294B
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an alternative to the traditional glaucoma treatment and management paradigms. The company's iStent platform is the first MIGS device in the United States. Glaukos markets its products through direct sales force in the United States and other countries. It has distribution partners in Europe, the Asia Pacific, Latin America, and internationally.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $214.645B 22.45
Edwards Lifesciences (EW) United States $46.932B 32.30
Alcon (ALC) Switzerland $33.321B 28.69
STERIS (STE) Ireland $18.019B 22.42
Teleflex (TFX) United States $10.587B 17.18
Fresenius Medical Care AG KGaA (FMS) Germany $8.996B 9.03
Penumbra (PEN) United States $7.452B 1783.82
Globus Medical (GMED) United States $7.103B 36.11
Integer Holdings (ITGR) United States $2.367B 19.00
Nevro (NVRO) United States $1.556B 0.00
Paragon 28 (FNA) United States $1.534B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.246B 17.74
Artivion (AORT) United States $0.520B 0.00